Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo

被引:38
作者
Andersson, Y. [1 ]
Engebraaten, O. [1 ,2 ]
Fodstad, O. [1 ,2 ]
机构
[1] Univ Hosp, Rikshosp, Norwegian Radium Hosp, Dept Tumor Biol,Inst Canc Res, N-0310 Oslo, Norway
[2] Univ Oslo, Norwegian Radium Hosp, Fac Div, N-0310 Oslo, Norway
关键词
immunotoxin; apoptosis; cyclosporin; breast cancer; metastasis model; GROWTH-FACTOR RECEPTOR; CANCER CELL-LINE; PSEUDOMONAS EXOTOXIN; DOUBLE-BLIND; NUDE RATS; METASTASIS; APOPTOSIS; ANTIBODY; PROTEIN; SUPPRESSION;
D O I
10.1038/sj.bjc.6605312
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
BACKGROUND: The clinical use of immunotoxins (ITs) has been hampered by hepatotoxicity, and the induction of a strong human-anti-IT response. The human-anti-IT response results in neutralisation of the immunoconjugates, rendering repetitive treatment inefficacious. METHODS: We evaluated the combination of cyclosporin A (CsA) with various Pseudomonas exotoxin A-based ITs in human breast, cervical, and prostate cancer cell lines measured by protein synthesis, cell viability, and TUNEL assay. Furthermore, expression of essential proteins were analysed by western blot. We used cervical cancer model in nude rats to evaluate the anti-metastatic effect of the combination. The anti-immunogenic response by the CsA treatment was investigated in immunocompetent rats. RESULTS: The combination of CsA with ITs caused remarkable synergistic cytotoxicity, in several cancer cell lines, characterised by protein synthesis inhibition, decreased cell viability, and an increased apoptotic index. Furthermore, the combination strongly inhibited formation of metastases in a cervical cancer model in nude rats with a statistically significant increase in median survival time of the combination-treated animals, as compared with those receiving a suboptimal dose of IT alone. Notably, we found in immunocompetent rats that the anti-IT immunoresponse elicited by repeated administration of IT was efficiently abrogated by CsA; notably the antibody responds towards the highly immunogenic PE was shown to be prevented. CONCLUSION: The combination of ITs and CsA might constitute a significant improvement in the clinical potential of systemic IT treatment of cancer patients. British Journal of Cancer (2009) 101, 1307-1315. doi:10.1038/sj.bjc.6605312 www.bjcancer.com Published online 22 September 2009 (C) 2009 Cancer Research UK
引用
收藏
页码:1307 / 1315
页数:9
相关论文
共 35 条
[1]
AMP-activated protein kinase protects against anti-epidermal growth factor receptor-Pseudomonas exotoxin A immunotoxin-induced MA11 breast cancer cell death [J].
Andersson, Y ;
Le, H ;
Juell, S ;
Fodstad, O .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (04) :1050-1059
[2]
Downregulation of the antiapoptotic Mcl-1 protein and apoptosis in Ma-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin [J].
Andersson, Y ;
Juell, S ;
Fodstad, O .
INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (03) :475-483
[3]
ARCECI RJ, 1992, BLOOD, V80, P1528
[4]
QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[5]
Cyclosporine A and its non-immunosuppressive derivative NIM811 induce apoptosis of malignant melanoma cells in in vitro and in vivo studies [J].
Ciechomska, I ;
Legat, M ;
Golab, J ;
Wesolowska, A ;
Kurzaj, Z ;
Mackiewicz, A ;
Kaminska, B .
INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (01) :59-67
[6]
Inhibition of Akt kinase signalling and activation of Forkhead are indispensable for upregulation of FasL expression in apoptosis of glioma cells [J].
Ciechomska, I ;
Pyrzynska, B ;
Kazmierczak, P ;
Kaminska, B .
ONCOGENE, 2003, 22 (48) :7617-7627
[7]
IDENTIFICATION OF CALCINEURIN AS A KEY SIGNALING ENZYME IN LYMPHOCYTE-T ACTIVATION [J].
CLIPSTONE, NA ;
CRABTREE, GR .
NATURE, 1992, 357 (6380) :695-697
[8]
Engebraaten O, 1999, INT J CANCER, V82, P219, DOI 10.1002/(SICI)1097-0215(19990719)82:2<219::AID-IJC12>3.0.CO
[9]
2-#
[10]
Engebraaten O, 2000, INT J CANCER, V88, P970, DOI 10.1002/1097-0215(20001215)88:6<970::AID-IJC21>3.0.CO